Cord Blood Transplantation in Children and Young Adults With Blood Cancer (NCT07566377)

🧪 Interventions in This Study

• Cord Blood Units (BIOLOGICAL)
• Cyclophosphamide (DRUG)
• Fludarabine (DRUG)
• Clofarabine (DRUG)
• Busulfan (DRUG)
• Thiotepa (DRUG)
• Tacrolimus (DRUG)
• Mycophenolate Mofetil (DRUG)
• Cyclosporine (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. A patient cannot be considered eligible for this study unless ALL of the following conditions are met. ° Disease type Cohort 1, High Risk Disease: Patients with age ≤ 26 years at the time of informed consent with no available and suitably matched related or unrelated donor within 4 weeks, with one of the following diagnoses: I. Acute myelogenous leukemia (AML):
2. Complete first remission (CR1) with blast count \< 5% by bone marrow morphology at high risk for relapse such as any of the following:
3. Known prior diagnosis of myelodysplasia (MDS)
4. High risk cytogenetics (e.g., those associated with MDS, abnormalities of 5, 7, 8, complex karyotype) and/or high-risk molecular abnormalities (e.g., TP53)
5. Requirement for 2 or more inductions to achieve CR1
6. Therapy-related AML (t-AML) or therapy-related myeloid neoplasm (t-MN) (including after therapy for other malignancy, and/or gene therapy or cell therapy)
7. Presence of Minimal/Measurable Residual Disease (MRD+) by cytogenetics, flow cytometry or molecular methods (at End of Induction or End of Consolidation)
8. Other high-risk features not defined above.
9. Complete second remission (CR2) or subsequent remission, with blast count \< 5% by bone marrow morphology
10. Presence of MRD by multiparameter flow cytometry at pre-transplant evaluation is acceptable. II. Acute lymphoblastic leukemia (ALL):
11. Complete first remission (CR1) with MRD negative status by multicolor flow cytometry, at high risk for relapse such as any of the following:
12. Presence of any high risk cytogenetic abnormalities such as t(9;22), t(1;19), t(4;11) or other, KMT2A (11q23) or other high risk molecular abnormality

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

• Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York

📞 Contact the Study Coordinator

Phone: (800) 525-2225

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Acute Myelogenous Leukemia

• Allo HSCT Using RIC and PTCy for Hematological Diseases — Minneapolis, Minnesota
• Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia — Los Angeles, California
• ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis — Cleveland, Ohio
• The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen — Winston-Salem, North Carolina
• ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies — Orange, California

Explore by condition: All Acute Myelogenous Leukemia clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.